4Tannock IF,de Wit R,Berry WR,et al.Docetaxel plus prednisone or mitoxantrone plis prednisone for advanced prostate cancer.N Engl J Med,2004,351:1502-1512.
5Petrylak DP,Tangen CM,Hussain HM,et al.Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.N Engl J Med,2004,351:1513-1520.
6Jemal A,Bray F,Center MM,et al.Global cancer statistics.CA Cancer J Clin,2011,61:69-90.
7Jemal A,Siegel R,Xu J,et al.Cancer statistics,2010.CA Cancer J Clin,2010,60:277-300.
8Boyle P,Ferlay J.Cancer incidence and mortality in Europe 2004.Ann Oncol,2005,16:481-488.
9Eisenberger M,Garrett-Mayer ES,Ou Yang Y,et al.Multivariate prognostic nomogram incorporating PSA kinetics in hormonerefractory metastatic prostate cancer (HRPC).J Clin Oncol,2007,25:5058.
10Tannock I,Osoba D,Stockler MR,et al.Chemotherapy with mitoxantrone plus prednidone or prednisone alone for symptomatic hormone-resistant prostate cancer.A Canadian randomized trial with palliative endpoints.J Clin Oncol,1996,14:1753-1755.
